Conflicts cause FDA to review advisory committees

Kondro, Wayne
July 2006
CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p23
Academic Journal
This article reports on a major internal review that was announced by the U.S. Food and Drug Administration (FDA) for its Advisory Committee Meeting system. The aspects of the review are highlighted. The FDA allows conflicted scientists to apply for a waiver that permits them panel membership on the condition that their individual expertise outweighs the seriousness of the conflict. One critic of the appointment of conflicted scientists was Congressman Maurice Hinchey (D.-NY).


Related Articles

  • Congress asks for investigation of FDA resources and staffing. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);3/8/2008, Vol. 336 Issue 7643, p525 

    The article focuses on investigation which have been asked for by committees of the U.S. Congress in 2008. The investigation has been requested to determine whether the U.S. Food and Drug Administration (FDA) has the resources and staffing which is necessary to do its job of protecting the U.S....

  • Ties between docs, companies under scrutiny on Capitol Hill.  // Medical Device Daily;2/29/2008, Vol. 12 Issue 41, p2 

    The article reports on a letter of inquiry sent by Charles Grassley, a member of the U.S. Senate Finance Committee, regarding potential financial conflicts of the doctors involved in the research on an artificial spinal disk that led to its approval by the U.S. Food and Drug Administration. The...

  • Conflict-of-Interest Policy Stymies Drug Review. Wechsler, Jill // Pharmaceutical Executive;Jan2010, Vol. 30 Issue 1, p16 

    The article reports on the move of the Food and Drug Administration (FDA) to seek panels/committee consisting of scientists and clinicians who can meet the stiffer conflict-of-interest standards in the U.S. As part of it, the FDA is screening 400 advisors and cleared 90 percent of them. The FDA...

  • Stupak to pursue shutdown of DTC gene testing operations. McCARTY, MARK // Medical Device Daily;7/23/2010, Vol. 14 Issue 142, p1 

    The article deals with the legislative hearing held by the U.S. House Energy and Commerce subcommittee in July 2010. Particular focus is given on companies involved in providing direct-to-consumer (DTC) gene testing. The accuracy of such test was questioned by Representative Bart Stupak...

  • Congress to examine FDA's action on Cordis violations.  // Medical Technology & Devices Week;8/20/2007, Vol. 5 Issue 34, p4 

    The article reports on an investigation that will be conducted by the U.S. House Energy and Commerce Committee into the action taken by the U.S. Food Drug Administration (FDA) on Cordis violations. Cordis is the manufacturer of the Cypher drug-eluting stent. FDA Commissioner William Hubbard has...

  • Hinchey introduces bill for FDA reform. Dickinson, James G. // Medical Marketing & Media;Jul2005, Vol. 40 Issue 7, p12 

    Reports that Congressman Maurice Hinchey has introduced the U.S. Food and Drug Administration Improvement Act of 2005. End of user fee program.

  • Congressman penalizes FDA over lawyer's help to pharmas.  // Medical Marketing & Media;Sep2004, Vol. 39 Issue 9, p17 

    The article reports that the U.S. Food and Drug Administration (FDA) chief counsel, Daniel Troy interceding in state civil suits on behalf of drug and medical device manufacturers. These manufacturers are accused of harming patients who had used their products. Republican Maurice Hinchey has...

  • Grandfathered carbinoxamine comes under FDA scrutiny.  // Drug Store News;7/17/2006, Vol. 28 Issue 9, p20 

    The article reports that the Food and Drug Administration has conducted investigations with prescription products containing the antihistamine carbinoxamine to ensure the safety of American's health in the U.S. Carbinoxamine is frequently used in cough and cold products. The federal agency has...

  • China helping on drug adulteration. Dickinson, James G. // Medical Marketing & Media;Nov97, Vol. 32 Issue 11, p34 

    Reports on the Chinese government's cooperation with the US Food and Drug Administration (FDA) in the investigation of adulterated drugs originating in China.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics